Dale Kevin Michael Handley

Mr. Dale Kevin Michael Handley


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2025 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
DHDale Kevin Michael Handley
Dale Kevin Michael Handley
AGAlexandra C Gillett
Alexandra C Gillett
RBRenu Bala
Renu Bala
JTJessica Tyrrell
Jessica Tyrrell
CLCathryn M Lewis
Cathryn M Lewis
Introduction: Frequent glycated hemoglobin A1c (HbA1c) monitoring is recommended in individuals with type 2 diabetes mellitus (T2D). We aimed to identify distinct, long-term HbA1c trajectories following a T2D diagnosis and investigate how these glycemic control trajectories were associated with health-related traits and T2D complications. Research design and methods: A cohort of 12,435 unrelated individuals of European ancestry with T2D was extracted from the UK Biobank data linked to primary care records. Latent class growth mixture modeling was applied to identify classes with similar HbA1c trajectories over the 10 years following T2D diagnosis. Associations between HbA1c class membership and sociodemographic factors, biomarkers, polygenic scores, and T2D-related outcomes, were tested using logistic regression and Cox proportional hazards models. Results: Six HbA1c trajectory classes were identified. The largest class (76.8%) maintained low and stable HbA1c levels over time. Five additional smaller classes with distinct, but more variable, trajectories were found and were associated with younger age at T2D diagnosis, higher fasting glucose levels, higher random glucose levels, higher body mass index polygenic score and increased healthcare use before T2D diagnosis. Relative to the low and stable class, these five showed increased risks of T2D complications, including stroke (HR=1.55 (1.31–1.84)), kidney disease (HR=1.39 (1.27–1.53)), all-cause mortality (HR=1.36 (1.23–1.51)), and progression to combination therapy (HR=3.22 (3.04–3.41)) or insulin (HR=3.21 (2.89–3.55)). Conclusion: Individuals with T2D who show higher and more variable HbA1c trajectories are at increased risk of developing T2D-related complications. Early identification of patients at risk, based on factors such as age at diagnosis and previous healthcare utilization could improve patient outcomes.

8 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CLChris Wai Hang Lo
Chris Wai Hang Lo
DHDale Kevin Michael Handley
Dale Kevin Michael Handley
OPOliver Pain
Oliver Pain
MKMichelle Kamp
Michelle Kamp
AGAlexandra C. Gillett
Alexandra C. Gillett
CLCathryn Lewis
Cathryn Lewis
Linkage between population-wide biobanks and electronic health records (EHRs) opens new opportunities to study the genetic and epidemiological underpinnings of treatment outcomes, a key step forward in delivering precision medicine. However, challenges include complexities in data extraction for longitudinal analyses, and the absence of reproducible phenotyping algorithms. Here, we present T-Rx, an open-source R package to streamline the processing of prescription and dispensing records, to enable reproducible and scalable analysis across EHR databases. T-Rx consists of three modules to derive treatment-related phenotypes from uncleaned prescription records: (1) Extraction and Imputation Module for extracting and imputing prescription details; (2) Exposure Ascertainment Module for converting prescriptions to longitudinal exposure periods; and (3) Phenotyping Module for creating reproducible proxy phenotypes that capture treatment and response patterns. We tested the utility of T-Rx in UK Biobank primary care records, with strength and quantity information extracted and imputed for 2,721,921 antidepressant and 430,705 antipsychotic prescriptions. The extraction functions were validated using oral hypoglycemic agent prescriptions in Clinical Practice Research Datalink Aurum, showing comparable performances to extraction using the NHS Dictionary of Medicines and Devices (dm+d) codes. The Exposure Ascertainment Module of T-Rx converts discrete prescription or dispensing events into longitudinal exposure periods in one-line R commands, with customizable parameters to account for real-world treatment complexities. The Phenotyping Module takes prescriptions as direct user input and returns analysis -ready data frames. Current phenotyping algorithms include antidepressant switching and treatment-resistant depression. The phenotyping functions also allow flexible parameter choices, such as treatment episode windows, definitions for switching and quality control criteria. Researchers can contribute phenotyping algorithms to T-Rx for reproducible use. T-Rx improves the accessibility of prescription information in biobanks, and analysis of dosage- and treatment-patterns across therapeutic areas. T-Rx contributes to open science through harmonized phenotypic definitions and reproducible analyses of proxy treatment outcomes.

10 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
CLChris Wai Hang Lo
Chris Wai Hang Lo
AGAlexandra C. Gillett
Alexandra C. Gillett
MIMatthew H. Iveson
Matthew H. Iveson
MKMichelle Kamp
Michelle Kamp
CFChiara Fabbri
Chiara Fabbri
CLCathryn Lewis
Cathryn Lewis
Background: Selective serotonin reuptake inhibitors (SSRIs) are a first-line pharmacological therapy in major depressive disorder (MDD), but treatment response rates are low. Clinical trials lack the power to study the genetic contribution to SSRI response. Real-world evidence from electronic health records provides larger sample sizes, but novel response definitions are needed to accurately define SSRI non-responders. Methods: In UK Biobank (UKB) and Generation Scotland, SSRI switching was defined using a ≤ 90-day gap between prescriptions for an SSRI and another antidepressant in primary care. Non-switchers were participants with ≥ 3 consecutive prescriptions for an SSRI. In UKB, clinical, demographic and polygenic score (PGS) associations with switching were determined, and the common-variant heritability was estimated. Results: In UKB, 5,133 (13.2%) SSRI switchers and 33,680 non-switchers were defined. The mean time to switch was 28 days (IQR: 17-49). Switching patterns were consistent across UKB and Generation Scotland (n = 498 switchers). Higher annual income and educational levels (OR [95% CI] for university degree: 0.73 [0.67-0.79], compared to no qualifications) were associated with lower levels of switching. PGS for non-remission, based on clinical studies, were associated with increased risk of switching (OR: 1.07 [1.02-1.12], p=0.007). MDD PGS and family history of depression were not significantly associated with switching. Using GCTB, the heritability of SSRI switching was approximately 4% (SE: 0.016) on the observed scale. Conclusion: This study identified SSRI switching as a proxy of non-response, scalable across biobanks with EHR, capturing demographic and genetics of treatment non-response, and independent of MDD genetics.

20 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
AGAlexandra Claire Gillett
Alexandra Claire Gillett
DHDale Kevin Michael Handley
Dale Kevin Michael Handley
RBRenu Bala
Renu Bala
KYKatherine Young
Katherine Young
JTJess G Tyrrell
Jess G Tyrrell
CLCathryn Lewis
Cathryn Lewis
Aims: To investigate the association between depression history, timing, and progression of diabetes treatment in type 2 diabetes (T2D). Methods: We conducted a cohort study using primary care records from the Clinical Practice Research Datalink Aurum database (2011–2023). Adults with T2D initiating oral glucose-lowering monotherapy (index) were included. Depression history, identified using clinical codes, was categorised by the most recent code before index: recent (≤1.7 years), intermediate (1.7–12.8 years), distant (>12.8 years), or none. Outcomes were time to treatment intensification (adding or switching drug class) and insulin initiation. We used Royston-Parmar survival models to estimate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for demographic and clinical variables. Results: Among 378,935 included individuals, 25.1% had a history of depression. Compared with no prior depression, recent depression was associated with higher odds of treatment intensification (OR 1.20, 95% CI: 1.17-1.23) and insulin initiation (OR 1.29, 95% CI: 1.23-1.36). Intermediate and distant depression were also associated with higher progression-odds, though more modestly. Conclusions: Depression, particularly recent episodes, is associated with earlier treatment progression in T2D, highlighting the importance of integrating mental and physical healthcare in diabetes management.

7 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DHDale Kevin Michael Handley
Dale Kevin Michael Handley
RBRenu Bala
Renu Bala
KYKatherine Young
Katherine Young
CLChris Wai Hang Lo
Chris Wai Hang Lo
JTJessica Tyrrell
Jessica Tyrrell
AGAlexandra C Gillett
Alexandra C Gillett
Background Frequent and consistent Glycated Haemoglobin (HbA1c) measurement is required for effective management of Type 2 diabetes (T2D). Co-morbid depression is an important driver of poor health and mortality in individuals with T2D. Little is known about how engagement with primary care for T2D management differs in individuals with co-morbid depression, and how this impacts all-cause mortality. Methods Adults with T2D were identified in the Clinical Practice Research Datalink Aurum dataset. Glycaemic testing frequency was defined as the number of HbA1c measurements per year after diagnosis. Conway-Maxwell-Poisson mixed effects models were used to test the associations between glycaemic testing frequency and T2D co-morbidities, pre-existing and incident depression (after T2D diagnosis), and depression severity. Cox proportional hazard models were used to determine the association of these variables with all-cause mortality. Results In total, 470,225 individuals with T2D were included. Of these, 20.1% and 6.1% had pre-existing and incident depression, respectively. Younger age, male sex, and non-White self-reported ethnicity were robustly associated with lower glycaemic testing frequency. In contrast, higher deprivation, pre-existing depression (IRR:1.06, CI: 1.05 – 1.07, p = 6.5×10-11), incident depression (IRR:1.04, CI: 1.03 – 1.05, p = 5.5×10-11) and a higher incident comorbidity score were associated with more frequent HbA1c testing. Pre-existing depression, incident depression, and depression severity were associated with increased risk of all-cause mortality after adjusting for HbA1c testing frequency (incident depression HR: 1.41, CI: 1.37 – 1.45, p = 3.7×10-97). In the entire cohort, higher HbA1c testing frequency was associated with reduced risk of all-cause mortality (HR: 0.93, 95% CI: 0.92 – 0.94, p = 3.60×10-82). Conclusion Individuals with T2D and depression have more frequent glycaemic testing yet still face a higher risk of mortality. This suggests that increased engagement with primary care for glycaemic monitoring alone is not sufficient to offset the broader health risks associated with depression. Targeted interventions beyond increased routine diabetes monitoring may be necessary to reduce excess mortality among individuals managing both T2D and depression.

19 August 2026 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
JRJulien Roux
Julien Roux
DSDenis Seyres
Denis Seyres
JBJessica L. Buxton
Jessica L. Buxton
DHDale Kevin Michael Handley
Dale Kevin Michael Handley
GHGiulia Hofer
Giulia Hofer
CCClaudia Cavelti-Weder
Claudia Cavelti-Weder
Background/Objectives: Bariatric (or metabolic) surgery is the most effective treatment for severe obesity, resulting in sustained weight loss and rapid improvement in metabolic outcomes. However, it is currently unknown what molecular changes are induced by the surgery, how they relate to the health improvements, how early they occur, and whether they are maintained over time. Subjects/Methods: In this study, we characterised early gene expression changes following surgery in blood samples from the ‘Personalised Medicine for Morbid Obesity’ cohort. Results: We observed widespread changes in gene expression only a few days after surgery. Pathways related to immune response were affected, in particular with a decreased expression of the NF-κB pathway and neutrophil cytotoxic activity genes, suggesting a reduction of the inflammatory state typically associated with obesity. Metabolic signalling was also affected, with decreased expression of genes from pathways related to glucagon and insulin secretion, and key regulators such as the appetite-controlling hormone ghrelin. Comparisons to publicly available transcriptomics datasets showed that beyond these specific changes, bariatric surgery induces a transcriptome-wide reversal of expression changes associated with obesity and with forms of type 2 diabetes related to obesity. Comparisons to transcriptomics studies with longer-term follow-ups after bariatric surgery showed that a large fraction of early-induced expression changes likely persist for several months. Conclusions: Taken together, we show that previously unreported early changes in blood gene expression after bariatric surgery provide in-depth insights into the resolution of the chronic inflammation associated with severe obesity and its connection with metabolic improvement.